This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Gw Research Limited. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Innovations of Fabio Iannotti in Cannabinoid Treatments
Introduction
Fabio Iannotti is an innovative inventor based in Pozzuoli, Italy. He has made significant contributions to the field of medical treatments, particularly focusing on the use of cannabinoids for therapeutic purposes. His work aims to address degenerative skeletal muscle diseases, which can have profound impacts on patients' quality of life.
Latest Patents
Iannotti holds a patent for the "Use of cannabinoids in the treatment of degenerative skeletal muscle diseases." This invention specifically targets Duchenne muscular dystrophy (DMD), a severe form of muscular dystrophy. The patent highlights the potential of cannabinoids, including Cannabidiol (CBD), Cannabidivarin (CBDV), and Tetrahydrocannabivarin (THCV), in providing therapeutic benefits for patients suffering from this debilitating condition. He has 1 patent to his name.
Career Highlights
Fabio Iannotti is associated with GW Research Limited, a company known for its focus on cannabinoid research and development. His work at the company has positioned him as a key figure in exploring the medical applications of cannabinoids. His research is paving the way for new treatment options for patients with degenerative muscle diseases.
Collaborations
Iannotti has collaborated with notable researchers in the field, including Vincenzo Di Marzo and Colin Stott. These collaborations have enhanced the depth and breadth of his research, contributing to the advancement of cannabinoid therapies.
Conclusion
Fabio Iannotti's innovative work in the use of cannabinoids for treating degenerative skeletal muscle diseases represents a significant advancement in medical research. His contributions are vital for developing new therapeutic options for patients affected by conditions like Duchenne muscular dystrophy.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile